Full text is available at the source.
Abstract
Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the clinical use of incretin-based therapies for type 2 diabetes mellitus and obesity.
- Incretin-based therapies are increasingly used for managing type 2 diabetes and obesity.
- Concerns have been raised regarding their association with neuropsychiatric issues.
- The extent to which risks vary among different generations of incretin-based therapies is not yet clear.
Simplified